Sandoz Partners With Fresenius Unit mAbxience On Licensing, Development, Manufacturing And Commercialization For An Emicizumab Biosimilar Candidate
Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.The agreement is consistent with mAbxience's strategy of broadening patient access to
Sandoz and mAbxience are teaming up to make a cheaper copy of an important hemophilia A medicine. This shows both companies are working hard to help more patients get treatments they need.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.